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Abstract
Objectives The aim of this review was to map the currently available evidence
on acceptability of oral paediatric medicines to aid in the selection of suitable
platform formulations for the development of new acceptable paediatric
products.
Methods This process used a defined search strategy of indexed publications and
included methods to assess the quality of the evidence retrieved.
Key findings Taste/palatability was the most extensively studied area of paedi-
atric medicine acceptability yet standard methods or criteria that define what is
classed as acceptable to children is still to be defined. There have been many
reports on the acceptability of medicines to paediatric populations yet major gaps
in the acceptability knowledge base exist including the shape and dimensions of
tablets, minitablets and capsules swallowed whole in infants and children; size
and overall volume of multiparticulates; volume of liquids completely swallowed
in infants and children; duration of retention within the oral cavity, size and taste
of orodispersible tablets, lozenges and chewable tablets and the number of solid
units dosed at each time point.
Conclusions The review highlights where further information is required to
support knowledge around acceptability of age-appropriate medicines. An algo-
rithm to aid in selection of a formulation that is likely to be acceptable based on
the age range to be treated by the medicine is presented as a result of this review.
Introduction
There is much evidence to support the need for age-appro-
priate medicines to treat paediatric patients. Pharmaceuti-
cal products for the paediatric population have a number
of considerations that may not apply to adult products. In
particular, the acceptability of a product needs to be clearly
defined for paediatric populations and this is currently an
area of great interest.
The importance and incentive to study the acceptability,
including palatability, of paediatric formulations was dis-
cussed in the reflection paper[1] and endorsed in the latest
European Paediatric guideline on pharmaceutical develop-
ment of formulations for paediatric use.[2] Before this regu-
latory change, there was no requirement for medicines to
be demonstrated to be acceptable to children. Guidance
issued by the European Medicines Agency (EMA) in 2013
states that patient acceptability must be an integral part of
paediatric formulation development and described in the
paediatric investigation plan (PIP).[3] Acceptability has pre-
viously been defined as ‘an overall ability of the patient and
caregiver (defined as “user”) to use a medicinal product as
intended (or authorised)’.[4] The palatability of paediatric
medicines is one of the most important formulation factors
in the acceptability of liquid medicines with potential to
influence adherence to therapeutic regimens and out-
comes.[5] Palatability has been defined as, ‘the overall
appreciation of a (often oral) medicine by organoleptic
properties such as vision (appearance), smell, taste, after-
taste and mouth feel (e.g. texture, cooling, heating, trigemi-
nal response), and possibly also sound (auditory clues)’.[4]
A better understanding of acceptability of paediatric
medicines offers advantages to the pharmaceutical industry
and patients. The pharmaceutical industry will benefit from
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a standardisation of approaches to the development of pae-
diatric medicines, a reduction in duplication of efforts, and
reduced development times and the associated costs for the
development of paediatric medicinal products. Patients
benefit by having access to medicines known to be accept-
able both during clinical evaluation and for subsequent
therapy with a better clinical outcome and improved qual-
ity of life. Furthermore, an understanding of acceptable for-
mulations reduces the barrier to the development of new
age-appropriate formulations of existing medicines.
A lack of knowledge about what is currently considered
to be acceptable to paediatric patients hinders the develop-
ment of acceptable, age-appropriate medicines. Regulatory
guidelines have been published although these have been
criticised as they are not based on scientific evidence (e.g.
Ref. [2]). This review article gathers the available evidence
to provide a much needed, single source of information on
which paediatric formulations should be selected based on
their acceptability to children. The wide range of evidence
from a broad spectrum of study types was effectively
mapped, thereby highlighting areas where acceptability is
understood and where possible future reviews or primary
research is required. Presentation of these results in an
accessible and summarised format assists policy makers for
guideline development and those working in pharmaceuti-
cal industry.[4]
Methods
Information on acceptability of medicines was sought from
a literature search and also ‘grey’ literature including con-
ference proceedings. Overall, the methods for the review
protocol were informed by the Cochrane Handbook for
Systematic Reviews of Interventions.[6] This review was
limited to the primary critical attributes in acceptability
testing as identified by Kozarewicz[4] and was limited to
oral dosage forms (Table 1).
Relevant data on each critical parameter were sought
from the literature to gather evidence on what is currently
known or suggested to be acceptable. The literature search
identified indexed publications by searching Scopus,
PubMed, Embase and Medline. Search key words included
the following: acceptability OR preference AND medicine
AND (child OR infant OR paediatric OR paediatric) AND
(palatability OR taste OR smell) OR (size OR shape OR
appearance OR swallowability) OR (dose adjustment OR
manipulation OR device) OR dose frequency.
The process to identify the most relevant research
included the following: screening of titles and abstracts;
selection of studies based on inclusion criteria with checks
from a second reviewer; searching of reference lists of
included studies and contacting experts for the details of
any unpublished or ongoing studies (EuPFI network
(www.eupfi.org) and consortium members within
SPaeDD-UK); and finally data extraction using a bespoke
data extraction table.
Only papers where information that specifically related to
acceptability attributes, as measured in paediatric popula-
tions, was extracted and included in the results; many papers
described the acceptability of dosage forms but did not con-
tain sufficient details on product parameters could not be
included. In addition, information about medicines that are
used clinically, yet approved before the need to demonstrate
acceptability, is included where relevant to highlight current
medical practice in paediatric populations.
The quality of the conclusions of this review is depen-
dent on the quality of studies included in the evidence base,
as poor quality studies are more likely to generate inaccu-
rate results. Many reviews that map the available evidence
do not include a quality assessment which is critical in the
use of this review to guide development of paediatric medi-
cines. The customised data extraction table used within this
review included a quality section where the robustness of
the evidence collected was categorised according to the type
of data presented. A summary of the criteria used to cate-
gorise evidence in terms of setting acceptability criteria is
presented in Table 2.
Table 1 Critical acceptability attributes in oral pharmaceutical
formulations for children as identified by Kozarewicz4
Dosage form Critical acceptability attributes
Monolithic solid dosage
forms to be swallowed
Size and shape, taste and
aftertaste for uncoated dosage
forms
Multiparticulate solid dosage
forms to be swallowed
Particle size, shape, texture
(surface aspects) and hardness
(grittiness); taste and aftertaste
for uncoated multiparticulate;
dose volume (quantity of
multiparticulate that needs to
be taken); need for a
measuring/counting device and
ease of administration
Solid dosage forms to be
chewed
Taste and aftertaste and the
mouth feel, smell, time needed
to chew and effort required to
chew (duration of
administration)
Solid dosage forms to be
dispersed (solubilised) in
the mouth (e.g. tablets
and lozenges)
Taste and aftertaste and the
mouth feel, smell, time needed
to dissolve/disperse (duration
of administration)
Liquid dosage forms –
solution, suspension
Taste and aftertaste; smell;
volume, viscosity and the
mouth feel; need for a
measuring device and ease of
preparation/administration;
visual aspects (overall appearance)
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Several literature sources include statements about the
acceptability of particular medicines in paediatric popula-
tions, many of these are based on the authors’ experience,
as clinical practitioners or in other roles and there are no
reported data to support these statements. In terms of regu-
latory requirements, it is considered essential to demon-
strate acceptability; therefore, such assumptions based on
experience are unlikely to be appropriate in setting accept-
ability criteria.
Results
Literature reports that define acceptability
Figure 1 shows the results of the search and the screening
of literature to identify studies to include in this review.
Twenty-nine papers were found that met the criteria to be
classified as strong evidence in determining the acceptabil-
ity of paediatric medicines; full details of these studies are
included as Table S1.
Scale methods were typically used to assess acceptability
or palatability with visual analogue scales and hedonic
scales being the most common. Other methods used
focused on a forced choice or preference between multiple
products to rank order in terms of taste or a simple ques-
tion as to whether the child would be prepared to take the
medicine again (e.g. Refs [7,8]). One study evaluated the
time taken for a nurse to administer the medicine as a mea-
sure of acceptability where it was stated that the average
administration time was 60 s.[9] Although measures of
acceptability and palatability are reported, there are very
few studies that define the limits or criteria for ‘acceptable’
products. The information in Table 3 reports the informa-
tion available on what the criteria for definition of accept-
ability was within published literature.
Interpretation of acceptability data is complex as there
are many different tools and criteria reported in the existing
literature.
Analysis of strong literature evidence on
acceptability
Monolithic solid dosage forms
Seven sources of strong evidence on the acceptability of
conventional monolithic dosage forms were identified and
a further five that related to minitablets (Table S1). Only
one study compared the acceptance of two different-sized
dosage forms (capsules size 2 vs size 0) as anticipated the
smaller capsule was preferred and resulted in increased
compliance.[20] Studies investigating solid dosage forms
that are small in size (2–3 mm), recognised as minitablets,
indicate that such formulations may be accepted by chil-
dren from birth (see Table 4).
Tablets up to 8 mm in diameter were demonstrated to
be acceptable (able to be swallowed whole) in children as
young as 2 years of age.[16,21,22] The number of tablets that
could be swallowed was only investigated for the minitab-
lets, where Kluk et al.[15] demonstrated that up to 10 mini-
tablets were acceptable to children from 2 years of age
when they were suspended in jelly to aid administration.
About 58% of children aged 2–3 were able to swallow 10
minitablets without chewing; many other children chewed
the tablets, which may limit their use to palatable immedi-
ate release formulations.
Tablets were demonstrated to be preferred to alternative
formulations (powders and liquids) in four studies.[14,23–25]
In a study conducted by Musiime et al.,[26] minitablets of
lopinavir/ritonavir were preferred by children (aged
6 months–6 years) in comparison with a syrup and a con-
ventional tablet. Children who could swallow conventional
tablets preferred these to minitablets due to the taste of the
minitablets. The dimensions of the conventional and
minitablets were not reported by the authors.[26]
Multiparticulate solid dosage forms to be
swallowed
Five sources of strong evidence were identified (Table S1)
all of which concluded that sprinkle/granule formulations
Table 2 Categorisation of evidence to support defining acceptable
limits for paediatric medicines
Type of evidence
Category
of evidence Setting acceptable limits
Peer-reviewed study
specifically evaluating
evidence of
acceptability in
children
Strong Appropriate to set
acceptability criteria
Data from a paediatric
investigation plan
(PIP) or PIP review
suggesting
acceptability in
children
Medium Likely to be appropriate to
set acceptability criteria
Peer-reviewed study
evaluating
acceptability in a
non-paediatric
population
Data from paediatric
medicines
approved before
the need for a PIP
Weak Although used in clinical
practice may be insufficient
to set acceptability criteria
Unsupported
statements within
the literature
No evidence Insufficient to set
acceptability criteria
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were well-accepted by children from 3 months of age.[10,26–
29] The studies also showed a preference for multiparticu-
lates over oral liquids. The size of multiparticulates or vol-
ume administered was not reported within most of the
studies.
Motte et al.[10] reported a study to measure the accept-
ability of prolonged release multiparticulates of sodium
valproate; the particles had a diameter of <400 lm;
although these were well-accepted in children (84.1% of
under 5s and 78.4% of over 5s reported it as acceptable) in
cases where parents struggled to treat children, 90% reported
that theconsistencyof theproductwas themain issue.
In a study to compare iron oral drops to multiparticulate
sprinkles in children, 92% expressed a dislike for the drops
by closing their mouth tightly or pulling a face, whereas
only 6.5% objected to taking the multiparticulate pro-
duct,[28] and this difference is attributed to the preference
of taste of multiparticulates. A study on 53 children (mean
age 6.7 years) revealed that multiparticulates were judged
to be significantly more palatable compared to the oral liq-
uid both by children and their parents.[27]
Solid dosage forms to be retained/dispersed/solu-
bilised in the mouth (tablets, films, wafers,
lozenges)
Dosage forms to be retained/dispersed in the mouth are
becoming more popular as a formulation for children.
Strong evidence identified included the following: three
studies on orally dispersible tablets[7,30,31] and one on a
lozenge.[13]
Orally dispersing tablets (ODT) of desmopressin were
favoured compared to conventional tablets in a study of
211 children aged 5–15 years.[30] This preference was
related to age with those under 12 years showing a statisti-
cally significant preference for the ODT product.[30] A
strawberry flavoured ODT was preferred to a peppermint
flavoured syrup in children aged 4–8 years; this difference
may be associated with the flavour rather than the dosage
form itself.[31] Cohen investigated the taste and acceptabil-
ity of ondansetron ODT compared to a placebo ODT. Each
child was asked to evaluate the tablet according to taste,
sensation and willingness to take the medication in future.
Potentially relevant 
references identified
(n = 2743)
Duplicates (n = 934) and 
Reviews/book chapters (n = 439)
Potentially relevant 
references screened by 
title (n = 1370)
Potentially relevant 
references screened by 
abstract (n = 623)
Excluded by review of title: did not fulfil 
inclusion/exclusion criteria
(n = 876)
Excluded by review of abstract: did not 
fulfil inclusion/exclusion criteria
(n = 494)
Full articles retrieved for 
detailed evaluation 
(n = 129)
Studies included in 
review
(n = 87)
Studies did not provide sufficient 
information regarding methodology used
(n = 42)
Studies identified as 
strong evidence in review
(n = 29)
Studies did not provide sufficient 
information regarding methodology used
(n = 58)
Figure 1 Flow diagram of study identification and selection.
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About 87% of the 31 children aged 5–11 stated that they
would be willing to take the ondansetron tablet again which
was the measure of acceptability of this dosage form used
within this study.[7] Overall ODTs appear to be an accept-
able dosage form in children over 5 years of age provided
they include appropriate flavouring agents.
Thompson et al.[13] compared the taste of strawberry vs
orange lozenges in children aged 6–12 years. Both were
judged to be acceptable, where the product was ranked as
‘good’, ‘really good’ or ‘supergood’ by 85.3% of partici-
pants for strawberry and 49% for orange flavour; in addi-
tion, 94% were willing to take strawberry product again
and 56% willing to take orange product again.
Liquid dosage forms, solutions, suspensions
Dispersible, soluble and effervescent tablets are solid dosage
forms which can be dispersed or dissolved in a liquid to form
a solution or suspension. These dosage forms require effec-
tive taste masking and have similar critical quality attributes
for acceptability as liquids as they are administered as a liquid
to the patient. Administration of tablets predispersed on a
spoon was reported in two studies; this type of formulation
has the benefits of stability of a tablet with the administration
being akin to a liquid which is more familiar to some chil-
dren and offers benefits to younger children. The overall
acceptability was good although there were reports of disper-
sion on the spoon being awkward for parents.[32]
The acceptability criteria for taste varied between studies:
a hedonic score greater than neutral was considered
acceptable in one case,[8] whereas a hedonic score of 2.7/5
(which is beyond neutral) was reported for a product
known to be unacceptable in another study.[12] Hedonic
scores were also used to rank the smell of four antibiotic
suspensions: cefdinir, amoxicillin/clavulanate, cefprozil and
azithromycin.[33] The resulting mean scores (of 5) for each
drug were the following: cefdinir = 3.97, amoxicillin/clavu-
lanate = 3.37, cefprozil = 3.95 and azithromycin = 3.95,
and all products were rated as having an acceptable smell
within this study. The percentage of participants agreeing a
product was acceptable was also used as a measure within
studies, and the lowest percentage in agreement where the
product was concluded to be acceptable was 70.5%.[32]
The volumes of liquid reported to be acceptable were
0.5 ml for neonates,[23] 2.5 ml for children from 1
to 4 years[24] although only 36–72% of children aged
0.5–6 years were able to fully swallow 3 ml of syrup.[14]
In studies where the liquid was a comparator, the alter-
native formulations were typically preferred: ODTs,[31]
multiparticulates[10,26–29] and minitablets.[17]
Discussion
Analysis of all evidence on acceptability
For this review, strong evidence was defined (Table 2) as a
peer-reviewed study that included data that specifically
Table 3 Summary of criteria for acceptability as defined within
studies
Defined limit of acceptability (or equivalent)
Study
reference
In a 2 face hedonic, these were considered as
acceptable or not; in the 4 face hedonic, this was
also the case for the negative two being
unacceptable and positive 2 being acceptable
[10]
Carers needed to state that the product was
equally or more acceptable to their child than
other medicines (70% of population agreeing
was used as basis for statistical powering)
[11]
Two products were included that were stated to be
acceptable and unacceptable in terms of taste
using a 5 point hedonic scale from 1 worst to
5 best
[12]
Acceptable taste = mean score of 3.4 in a five-point
hedonic scale
Unacceptable taste = mean score of 2.1 in a five-point
hedonic scale
Primary endpoint (of acceptability) was % of participants
with a score of >4 on the seven-point hedonic scale
[13]
Ability to swallow the dosage form whole (observed to
look for chewing, choking, aspiration)
[14–19]
Table 4 Literature data on acceptability of tablet/capsule size
(including minitablets) by age in paediatric populations
Age (years)
Dimensions swallowed
(including chewing/
splitting)
Dimension swallowed
whole
Neonate
(under
28 days)
2 mm[23] 82.2% can swallow 2 mm[23]
0.5 2 mm[14,17] 70% can swallow 2 mm[17]
1 4 mm[24] 60% can swallow 2 mm[17]
2 2–3 mm[15] 40% can swallow 2 mm[17]
~60% can swallow 2–3 mm[15]
46% can swallow 3 mm[18]
>80% can swallow 5 mm[16]
Can be trained to swallow
tablets up to 7–8 mm[16]
3 50% can swallow 2 mm[17]
53% can swallow 3 mm[18]
>80% can swallow 17.6 mm
(size 2 capsule)[20]
4 >75% can swallow 2 mm[14]
80% can swallow 2 mm[17]
>80% can swallow 7 mm[21]
5 100% can swallow 2 mm[17]
85% can swallow 3 mm[18]
6 91% can swallow 7 mm[22]
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evaluated acceptability of medicines within a paediatric
population; the definition did not explore methodology,
sample size, settings, etc. as this was outside of the scope of
this review (although some study details are included in
Table S1). This evidence was judged to be strong as the
study required ethical approval as well as peer review before
publication; therefore, the results and conclusions have
been externally validated.
Monolithic solid dosage forms
Size and shape
Problems relating to the sizes of solid dosage forms or
swallowing medicines have been reported in several stud-
ies,[34–39] yet the dimensions of the solid dosage forms were
not specified in these reports. ‘Pill-swallowing’ studies con-
ducted in children and young people with HIV have identi-
fied that young people fear that solid dosage forms may ‘get
stuck’ or cause choking.[40,41] Solids are only usually
acceptable postweaning.[42] The age at which most children
acquire the skills to swallow tablets and capsules safely has
been subject of much debate. Paediatric literature widely
quotes 6 years as a general age from which solid monolithic
dosage forms are considered suitable for children.[43] Some
children may already have acquired the ability to swallow
tablets and capsules from an earlier age or can be taught
using behavioural training interventions. For example,
Yeung and Wong[44] found that children with HIV as
young as 3 years were prescribed stavudine as a solid
dosage form. In a recent study in Uganda and Zimbabwe,
36% of children were able to swallow antiretroviral tablets
intact (mean age 3.3 years), while 64% required them to be
crushed or dispersed (mean age 2.9 years).[45]
In a review of approved PIPs for children aged 0–
11 years, 37 approved PIPs for monolithic tablets were
reported.[46] Size data were available on 24 of these tablets,
where two were small (0–4 mm), 15 were medium-sized
(5–9 mm) and four were large (>10 mm). There was little
information on how age correlated to tablet size within this
article although it was stated that two PIPs have been
agreed with tablets from 0 to 4 mm for children aged 2–
5 years. The shape of tablets in approved PIPs was reported
for 21 of the 37 approved monolithic tablets, 12 were
round, eight were oblong/caplet/oval and 1 was a specified
other shape.[46]
An evaluation of PIPs conducted by regulators con-
cluded that it is now increasingly accepted that small (0–
4 mm) tablets may be applicable in young children
(2–5 years), yet the use of medium-sized tablets (5–9 mm)
in this age group (2–5 years) is still discouraged, whereas
the use of large-sized tablets (>10 mm) is generally consid-
ered unacceptable because of swallowing difficulties and the
risk of choking.[46] Minitablets are often chewed by chil-
dren; therefore, it may be prudent to consider the develop-
ment of harder tablets if chewing is to be discouraged
(although it is important to also recognise the risk of dental
damage or choking with harder non-chewable tablets). The
EMA Paediatric Committee’s (PDCO’s) Formulation
Working Group (FWG) recommend that for younger
patients, those aged 6–8 years, tablets of 6–7 mm with
appropriate shape are acceptable.[47]
It is reported to be acceptable for patients/carers to split
tablets if score lines provide equal amounts[48]; there is evi-
dence from PIPs that tablets with a score line have been
approved.[46] PIPs have been approved for tablets larger
than 5 mm for children aged 2–5 years and tablets larger
than 10 mm for children aged 6–11 years.[46] The majority
of these larger tablets were reported to be immediate release
and film-coated tablets that may be broken, crushed or
chewed, unless bioavailability or patient acceptability is
affected.
Number of units per dose administration
Problems associated with the quantity of solid dosage forms
in children have been reported previously, typical issues
raised were tablet quantity or too much medication (e.g.
Refs [34–36,49–51]). The quantity of solid dosage forms
was reported as a main problem when administering
medicines to patients with HIV.[51]
In a study by Adams et al.,[52] the number of tablets that
parents/caregivers and healthcare workers thought was
acceptable for children in Tanzania to take as a single dose
was reported. Typically, one tablet was felt to be most
appropriate for children in early years of primary school
(under 8 years) rising to two tablets in last years of primary
school (9–12 years). The total number of tablets per day
rose to 3–6 for those in early years at primary school and
up to 6–9 for older children.
Van de Vijver et al.[53] reported that the overall accept-
ability of Creon capsules (capsule size not stated) decreased
as the number of capsules to be taken increased, although
the actual number of capsules was not reported. The PDCO
FWG state that the number of tablets, capsules or particles
to be administered must be easy to count and to administer
(e.g. 1–3 tablets).[47]
Taste and aftertaste of uncoated dosage forms
There are limited reports of the poor taste of solid dosage
forms; an example is the taste of nelfinavir tablets,[54]
although these are coated rather than uncoated tablets.
Typically neutral tasting medicines have been proposed by
the EMA for use in children particularly in the treatment of
chronic conditions.[3]
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Acceptable parameters for monolithic solid
dosage forms
In terms of evidence to support acceptability of monolithic
dosage forms, the information in Table 5 provides a sum-
mary of parameters likely to be acceptable to paediatric
populations.
Multiparticulate solid dosage forms to be
swallowed
Particle size, texture and hardness
For solid oral multiparticulate dosage forms, important
texture attributes include roughness, hardness, fracturabil-
ity and cohesiveness, depending on the specific form.[55]
Based on recent FDA guidance, multiparticulates which
are labelled for administration via sprinkling should have a
target size of 2.5 mm with no more than 10% variation
over this to a maximum size of 2.8 mm.[56] They report
that this size should ensure adequate mouthfeel and reduce
the risk of inadvertent chewing although it is not stated
whether this is based on adults or a paediatric population.
The multiparticulate sizes used in approved modified
release capsules labelled for sprinkling on food was
reported; the majority of products had multiparticulate
sizes of <1.5 mm.[57]
The administration may also impact upon the
mouthfeel, for example products administered directly
into the mouth are likely to feel more gritty than those
mixed with soft food before administration. Lopez
et al.[58] assessed the mouthfeel of spherical cellulose
multiparticulates dispersed in liquids in young adults
using a VAS from very smooth to very gritty. As antic-
ipated, the grittiness perception increased with both
concentration and particle size and the most pleasant
samples were associated with a low grittiness score.
Kimura et al.[55] evaluated the mouthfeel of particles of
a range of sizes in adults; the results showed that the
score of roughness increased within increasing particle
size; typically particles >300 lm were scored poorly.
Taste and aftertaste
The modified release granule formulation of valproate
(Depakine Chronosphere) was designed to be a tasteless
multiparticulate product to avoid issues with palatability
that were observed with the liquid product.[27] Several
studies have investigated the acceptability of micronutrient
powders delivered as a multiparticulate sprinkle (e.g. Refs
[59,60]); a major finding in these studies are that parents
like the product as it is neutral tasting with a neutral smell
and does not affect the taste of food with which it is admin-
istered.
Dose volume (quantity)
Children with cystic fibrosis (CF) are recommended to take
lipase doses of 400–800 units per gram of ingested fat; in an
infant of 10 kg (2 years old), this equates to eight scoops of
Table 5 Proposed acceptable tablet/capsule parameters based on ages of paediatric populations. Strong evidence is coloured green; medium evi-
dence is orange; weak evidence blue and no evidence is grey
Product attribute
Available evidence of acceptability
Neonates
(<1 month)
Infants
(1 month – 2 years) Child (2–5 years) Child (6–11 years)
Size 2 mm[23] 2 mm[17] 2 mm[14,17] 3 mm[18]
3 mm[18] 7 mm[22]
5 mm[16] 9 mm[46]
7 mm[21] 12.1 9 4.2 mm
17.6 mm[20]a
Shape Not appropriate Round[46] Round[46] Round/oblong/
caplet/oval[47]
Number of
units per dose
Not appropriate 1[52] 1[52] 1–2[52]
3[47] 3[47]
10 (minitablets
in jelly; total
volume < 5 ml)[15]
3[47]
Taste and aftertaste
of uncoated
dosage forms
Not appropriate Neutral[27] Neutral[27] Neutral[27]
aThis size capsule was acceptable to children with cystic fibrosis who are used to taking monolithic dosage forms; there is no evidence on
acceptability in other paediatric populations.
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multiparticulates (each scoop holds 100 mg) of Creon for
children to be administered daily with meals. Nelfinavir is
administered in large volumes, for instance, at the dose of
55 mg/kg BID, an average 6 year old is required to take 25
scoops (each scoop contains 50 mg; total administered is
1250 mg) of Nelfinavir powder, twice a day with food. This
‘large volume’ of Nelfinavir powder was reported to be
challenging for parents to administer.[61]
Delivery device
The EMA Paediatric Committee’s (PDCO’s) Formulation
Working Group (FWG) recommend that an appropriate
dispensing device should be available to enable measure-
ment of the required doses and to count multiparticu-
lates.[47] Infants and children with CF are recommended to
take lipase doses of 400–800 units per gram of ingested fat;
this is delivered either using Creon capsules (often split
and emptied in part) or Creon for children is a bulk con-
tainer of mini multiparticulates with a dosing scoop that
delivers 5000 lipase units per scoop (each scoop holds
100 mg). A study that compared parents (of children aged
6–36 months) preference for each dosage form reported
that the use of the scoop with the Creon product was
easier than opening capsules and that it was easier to mea-
sure the correct dose.[62]
Dose sipping technology has been developed to deliver a
single dose of small-sized pellets, overcoming swallowing
issues.[17,63] This technology incorporates small-sized pel-
lets in a straw; when the child holds the straw in a beverage
and sips, the drug is delivered in a ‘user friendly’ way. The
Coni-Snap sprinkle capsule has been developed which is
easy to open providing a useful delivery device for
multiparticulates.[64]
Acceptable parameters for multiparticulate solid
dosage forms
The parameters for multiparticulates that are likely to be
acceptable in paediatric populations are summarised in
Table 6.
Solid dosage forms to be chewed
Size and shape
No strong evidence was identified on the acceptable size of
tablets designed to be chewed (as compared to conventional
tablets that may be chewed by patients). Commercially avail-
able chewable tablets range from 9.5 mm for montelukast
tablets[65] for children over 2 years to 14.7 mm for sime-
thicone tablets for children over 6 years.[66]
Taste, aftertaste and mouthfeel
Historically, the majority of oral chewable dosage forms
have been hard and leave residual particles in the mouth
and teeth, which are features that children find unpleasant.
Wiet et al.[67] reported that softer chewy textures are pre-
ferred by children to harder, crunchier OTC medicine
forms, although this study was based on opinions and not
exposure to dosage forms.
There are many over the counter fruit-flavoured vitamin
tablets for children that are soft and designed to be chewed.
These are generally acceptable to children and they consti-
tute a significant commercial market.
Time needed to chew and effort required to chew
In typically developing children, primary teeth begin to
erupt from 6 months of age and the complete set of
Table 6 Proposed acceptable multiparticulate parameters based on ages of paediatric populations. Strong evidence is coloured green; medium
evidence is orange and no evidence is grey
Product
attribute
Available evidence of acceptability
Neonates
(<1 month)
Infants
(1 month–2 years)
Child
(2–5 years)
Child
(6–11 years)
Size <400 lm[10] <400 lm[10]
<300 lm[55] <300 lm[55]
2.5 mm[56] 2.5 mm[56]
Shape Round Round Round
Number of units
Taste and
aftertaste
of uncoated
dosage forms
Neutral[27] Neutral[27] Neutral[27]
Texture (grittiness)
Dose volume
Measuring device Scoop preferred to
capsule[62]
Scoop preferred to
capsule[62]
Scoop preferred to
capsule[62]
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20 have usually erupted between the ages of 2 and
3 years. Recent research suggests continual refinement
of chewing skills occurs until at least the age of
3 years, at which time chewing patterns and efficiency
also stabilise.[68] It has been reported that soft chewable
dosage forms such as gelatine gummy sweets may be
easier, more appealing and natural to chew for children,
compared to a chewable tablet.[69]
Researcher observational analysis discovered that chil-
dren under 2 years with neuroblastoma found it easier to
chew tablets as they were unable to swallow the tablets
whole.[70] Chewable tablets of Montelukast were preferred
to inhale cromolyn in a study of 266 children aged
6–11 years, although there were no details on the formula-
tion to report whether this was just a preference for oral
therapy compared to inhale or whether the chewable tablet
was particularly preferred.[71]
Solid dosage forms to be dispersed/
solubilised/eroded in the mouth (tablets,
films, wafers, lozenges)
Size and shape
No data exist on the acceptable size of orodispersible
tablets. Commercially available ODT have diameters
ranging from 9 to 17.5 mm. Products licensed for use
in children have diameters of 9.5 mm for acyclovir
used in children over 2 years[72]; Ondansetron dis-
persible tablets are licensed for use in children over
6 months and the Ratiopharm product has a diameter
of 6.5 mm.[73] FDA guidance suggests that the weight
of ODTs should be <500 mg, this is based on all ODTs
and not just those designed for use in paediatric
populations.[74]
There are limited published data on acceptable sized
dosage forms that can be retained within the mouth for
erosion. There are several marketed medicinal products
that are used in paediatric populations as well as neutraceu-
tical and vitamin products. Confectionary is known to be
well-accepted in children and there may be extensive
knowledge on preferred size and shape by age that could be
used to inform the development of paediatric formulations.
The size of the dosage form should be appropriate for the
size of the oral cavity of the child.
Ondansetron oral films (Setofilm) are listed in the
BNF-C for use in children over 6 months; these are 3 cm2
films that contain 4 mg drug[75]; fentanyl buccal films are
also listed in the BNF-C which range up to 3.11 cm2.
Flurbiprofen lozenges are licensed for use in children
and these are 19 mm in diameter, although they are
only licensed for use in children over 12 years of
age.[76]
Taste and aftertaste and mouthfeel
The taste of ODTs is important in maintaining acceptabil-
ity for children. There have been very few studies on the
taste of this type of dosage form.
The mouthfeel of ODTs has not been reported in the
literature although it would seem sensible to consider simi-
lar-sized particles to those delivered as multiparticulate
dosage forms are likely to be acceptable. The granule size
within ODT formulations was acceptable up to 244 lm
based on a study conducted in adults.[55]
Over the counter lozenges and films are available for
children, and these are typically fruit-flavoured products
containing vitamins and other supplements rather than
medicines.
Time needed to dissolve/disperse
FDA guidance defines an ODT as, ‘A solid dosage form
containing medicinal substances which disintegrates
rapidly, usually within a matter of seconds, when placed
upon the tongue’. The time taken for disintegration must
be 30 s or less, when based on the United States Pharma-
copeia (USP) disintegration test method or alternative.[74]
No literature was found on in-vivo dispersion times in chil-
dren although studies conducted in adults have reported
times of 29.4 s for complete oral disintegration of risperi-
done tablets[77,78] and 58 s for olanzapine tablets.[78]
Although orally dispersible tablets can be taken without
water, a study on Desmopressin revealed that 13% of chil-
dren did take the ODT with water[30] compared to 77%
with the conventional tablet formulation.
The European Pharmacopoeia states that orally dispers-
ing films should ‘disperse rapidly’, no further information
is provided regarding timelines for disintegration in vivo
and how the disintegration should be affirmed in vitro.[79]
Orally eroding dosage forms can be manufactured to
provide a range of erosion times to suit drug release and
subsequent therapy. There are no data on acceptable
erosion times in paediatric populations.
Liquid dosage forms, solutions, suspensions
Taste and aftertaste
The taste of medicines and how this is evaluated has previ-
ously been reported.[80] There are several examples of work
has been carried out on the assessment of medicine taste
(e.g. Refs [81–84]). Brand names are rarely reported within
the literature which limits the direct comparison between
studies as it is already known (and the focus of several stud-
ies) that therapeutic equivalents can have very different
tastes (e.g. Refs [12,13,85–94]). Evaluating an acceptable
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taste is difficult, the consensus from previous data seems to
suggest that a better than neutral response to a taste is an
acceptable taste.
Smell
The literature evidence on perceptions regarding the smell
of medicines is limited. Esteban Gomez et al. [95] reported
problems with smell on an average scaled measure ranging
from 0 to 5 (0 = causing no difficulties 5 = causing maxi-
mum difficulties with adherence). The average smell scores
were reported for the liquid: reverse transcriptase inhibitors
and protease inhibitors as 0.3 and 2.1, respectively. The
study found that the smell of protease inhibitors caused
moderate difficulties with adherence.[95]
Volume
Small volumes are normally better tolerated for prepara-
tions with known palatability issues, unless a more diluted
preparation may allow better taste masking. There are
issues in very small volumes of oral liquids for administra-
tion in children; these are generally related to the accuracy
of dosing relative to the devices available.[96] The typical
volume of medicine administered in a child is expected to
be swallowable in one unit; therefore, the maximum vol-
ume should equate to the volume of a swallow. The volume
of a swallow is reported to be 4.5 ml for children from
15 months to 3.5 years of age, and this equates to a typical
volume of 0.27 ml/kg.[97]
The EMEA report that typical target dose volumes
should be <5 ml for children under 5 years and <10 ml for
those 5 years and older.[43] Yet, there are examples of larger
volumes used with children routinely. Paracetamol suspen-
sion is available as 120 mg/5 ml or 250 mg/5 ml products,
and the recommended dose for a child of 2–3 years is
180 mg; this is likely to be administered as 7.5 ml of the
120 mg/5 ml product.[75]
Yeung and Wong[44] postulated that it may be the vol-
ume of liquid that is taken that drives the conversion to
solid dosage forms for children with HIV. The data in
Table 7 provide some support that large volumes are not
well-accepted, although there are other factors including
the taste of the liquids as well as its portability that also
need to be considered. In addition, there was no report as
to whether the tablets/capsules were taken whole or manip-
ulated before administration once the child converted to
the solid dosage form.
The major difference in products that require reconstitu-
tion by the patient is the volume of liquid consumed as this
is typically much larger than ready to use liquid products.
Research conducted in oral rehydration and activated char-
coal preparations has shown that children struggle to
swallow large volumes of unpleasant tasting liquids.[98,99]
Typical instructions for reconstitution are to disperse into a
glass of water before drinking; therefore, a reasonable
volume would be 100 ml or smaller if possible.
Mouthfeel/texture
There are very limited reports on the influence of texture of
medicines; Allue et al. (2012) evaluated the organoleptic
properties of oral rehydration solutions in children, includ-
ing the influence of texture by comparing a ‘gelatine’ and
‘gel’ texture; their results showed that the ‘gel’ texture was
preferred, although no further details on this finding were
provided.[100] The need to improve the texture of medici-
nes was also highlighted for antiretroviral therapies,[50,95]
although details on textural issues were not explicitly
reported.
There are no reports on the ideal mouthfeel of a liquid
medicine; yet it is intuitive to suggest that this needs to be
smooth and in the case of a bad tasting medicine, a product
that is swallowed rapidly and leaves minimal residue on the
oral cavity surfaces. Positive attributes of oral formulations
reported in a recent study described good textures as being
‘sherbet’ and ‘fizzy’.[101]
A recent study investigated barriers to medicines admin-
istration in children and although taste was the most
reported issue in medicines, refusal texture was the next
most frequent reason for refusal.[102] Specific medicines
identified with textural issues included lactulose which was
described as ‘oily’ and co-trimoxazole liquid described as
‘thick and gelatinous’.[101]
Need for a measuring device and ease of prepara-
tion
Liquids are typically administered via an oral syringe or
medicine spoon. It is essential that the dose is measureable
for all patients; there have been literature reviews published
recently on this topic (e.g. Ref. [103]). The device supplied
must be appropriate for the product and the doses required
by the patient.
Acceptable parameters liquid dosage forms
In terms of evidence to support acceptability of liquid for-
mulations, the information in Table 8 provides a summary
of parameters likely to be acceptable to paediatric popula-
tions.
Conclusions
Although there have been many reports on the acceptability
of medicines to paediatric populations, there are still major
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gaps in the knowledge base. The findings from this review
highlight the gaps in knowledge where additional research
is required to better understand acceptability of paediatric
medicines.
Although taste/palatability has been the most exten-
sively studied area of paediatric medicine acceptability,
there are still no recommended standard methods or cri-
teria that define what is classed as an acceptable liquid
or what flavours are acceptable to children. A defined
methodology or standard needs to be identified to sup-
port acceptable palatability claims in paediatric products.
Many palatability studies have been conducted in Wes-
tern populations, and there is a need to ensure that fla-
vours are acceptable where products will be distributed
globally. It is also essential to recognise that palatability
is broader than taste, and the impact of smell and tex-
ture should not be ignored.
Studies undertaken that assess the acceptability of dosage
forms in paediatric populations often do not report key
critical attributes of the formulation under test which limits
the breadth of their utility. Studies should report a greater
level of detail on formulation attributes. Primary research is
required to define the acceptability of the following: the
volume of liquid administered, the volume of multiparticu-
lates administered, the dimensions of tablet and minitablets
(including those designed to be retained in the mouth), the
size of multiparticulate granules, the time that products
should be retained in the mouth and the number of tablets
dosed at each time point.
Major gaps exist in the dimensions and number of
monolithic solid oral dosage forms that are acceptable to
children across all age ranges. Further primary research is
required to best understand the minimum age at which
tablets are likely to be accepted as this option often offers a
simple option in providing medicines to children.
Multiparticulate dosage forms are typically of interest as
they combine the stability of solid dosage forms with the
flexibility of liquids. Research is required to better
Table 7 Formulation factors and the age of conversion from a liquid to a solid formulation as reported by ref. [44] Product details and doses are
based on a 6-year-old, 20-kg child referenced from the BNF-C[75]
Drug Dose
Age of
conversion (years) Solid product details Liquid product details
Stavudine 20 mg twice daily 3.6 20 mg capsule
17.5 9 6.1 mm
1 mg/ml solution
20 ml twice daily
Abacavir 150 mg twice daily or 300 mg once daily 9.2 300 mg tablet 20 mg/ml
7.5 ml twice daily
Didanosine 250 mg daily 7.2 250 mg capsule
19.3 9 6.7 mm
20 mg/ml
12.5 ml daily
Lamivudine 75 mg twice daily or 150 mg once daily 10 150 mg tablet (scored)
13.9 9 6.9 mm
50 mg/5 ml
7.5 ml twice daily
Zidovudine 100 mg in the morning
200 mg in the evening
6.9 100 mg capsule
15.7 9 5.8 mm
50 mg/5 ml
10 ml in the morning
20 ml in the evening
Table 8 Proposed acceptable liquid parameters based on ages of paediatric populations. Strong evidence is coloured green and no evidence is
grey
Product
attribute
Available evidence of acceptability
Neonates
(<1 month)
Infants
(1 month – 2 years)
Child
(2–5 years) Child (6–11 years)
Volume <0.5 ml[23] 2.5 ml[24] 2.5 ml[24] ≤10 ml[43]
<5 ml[43] ≤5 ml[43] ≤5 ml[43]
Mouthfeel
Taste and
aftertaste
Score >50 mm on a VAS or
neutral to positive in a
hedonic scale in at least
70% of test population[10,12,104]
Score >50 mm on a VAS or
neutral to positive in a
hedonic scale in at least
70% of test population[10,12,104]
Smell Neutral smell Neutral smell At least 70% of test population
score smell as good or really
good[33]
At least 70% of test population
score smell as good or
really good[33]
Neutral smell Neutral smell
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understand the impact of particle size, volume adminis-
tered and method of administration in determining the
acceptability of multiparticulates to children although the
evidence to date looks promising.
Dispersible tablets, such as multiparticulates, offer bene-
fits of both solid and liquid dosage forms. There are prod-
ucts that disperse in a small volume (<5 ml), directly
within the mouth or within a glass of water. The taste of
these products is typically the key attribute investigated, yet
it is important to also consider additional aspects of orally
disintegrating products including the dimensions and dura-
tion for retention. The evidence suggests that with appro-
priate taste masking, orally dispersible tablets can be
acceptable to children over 5 years of age.
The PDCO FWG recommend that acceptability, includ-
ing palatability testing, should be performed during clinical
trials in target patients’ population.[47] This encourages
acceptability testing to be conducted as part of the clinical
development of a product, yet it is important that product
development follows the path where the final product is
likely to be acceptable to the relevant population to avoid
delays in the availability of age-appropriate medicines to
children.
The evidence within this review was used to create an
algorithm that may help in the design of age-appropriate
medicines (Figure 2). It is envisaged that this algorithm will
be useful to those developing oral medicines for children to
ensure they select a formulation that is likely to be accept-
able to the patient. It is anticipated that this algorithm will
be developed further as more evidence becomes available.
It is essential that high-quality research is undertaken to
address current gaps in knowledge to ensure that efforts in
development are focussed on products that are highly likely
to be acceptable to the relevant paediatric population. The
output of studies on acceptability needs to be disseminated
in peer-reviewed journals and include sufficient detail on
the formulation attributes to understand acceptability of
medicines to children.
Liquid 
(including 
dispersible 
tablet or 
granules for 
reconstitution)
Conventional
or mini
monolithic 
tablet
Multi-
particulate
Orodispersible 
tablet
Chewable 
tablet
Will the 
medicine 
be used to 
treat 
neonates?
→Yes→
<0.5 mL 
volume
Neutral taste
2 mm 
minitablet 
acceptable
X X X
↓
No
↓
Will the 
medicine 
be used to 
treat 
infants?
→Yes→
<2.5 mL 
volume
Neutral taste
<3 mL
tablet
Up to 3 
tablets per 
dose
Neutral 
taste
<6.5 mm 
tablet
Neutral taste
X
↓
No
↓
Will the 
medicine 
be used to 
treat 
children 
aged 2-5 
years?
→Yes→
<2.5 mL 
volume
Neutral taste
Up to 10 
minitablets 
acceptable
<4 mm tablet
Up to 3 
tablets per 
dose
Neutral 
taste
<9.5 mm 
tablet
Neutral taste
<9.5 mm 
tablet
Neutral 
taste
↓
No
↓
Will the 
medicine 
be used to 
treat 
children 
aged 6-12 
years?
→Yes→
<10 mL volume
Neutral taste
<7 mm tablet
Up to 3 
tablets per 
dose
Neutral 
taste
<9.5 mm 
tablet 
Neutral taste
<14.7 mm 
tablet
Neutral 
taste
Figure 2 Proposed (based on the evidence in this review) algorithm to select an acceptable age-appropriate medicine.
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